GlassScriptPhysician profile
Amber Amberson
NPI 1689301046
$5,647.13
in general payments reported to CMS, 2019-2025
25 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $1,480 · 2024: $1,726 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.48 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $798.52 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $746.35 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $459.39 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $360.63 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $298.17 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $292.08 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $275.93 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $253.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $203.17 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $179.69 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $133.35 | 2022-2024 | Gimoti |
| Ironwood Pharmaceuticals, INC | $102.98 | 2023-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $93.50 | 2023-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $91.87 | 2023-2025 | Epclusa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $66.46 | 2022-2024 | Zeposia |
| Intra-Sana Laboratories | $61.55 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Nestle Healthcare Nutrition INC. | $45.59 | 2023 | |
| Orphalan INC | $43.55 | 2024 | Cuvrior |
| Braintree Laboratories, INC. | $32.27 | 2023-2024 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $30.75 | 2022 | |
| Merck Sharp & Dohme LLC | $30.33 | 2023 | Dificid |
| Novo Nordisk INC | $21.54 | 2025 | Wegovy |
| Redhill Biopharma INC. | $17.84 | 2024 | Talicia |
| Lilly USA, LLC | $14.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Amberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.